NEW YORK, February 27, 2017 /PRNewswire/ --
Four US Biotech equities have been lined up by Stock-Callers.com for evaluation today, and they are: Anthera Pharmaceuticals
Inc. (NASDAQ: ANTH), Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR), Pacific Biosciences of California Inc. (NASDAQ: PACB), and
Conatus Pharmaceuticals Inc. (NASDAQ: CNAT). According to an article on ETF Trends, market observers are growing more bullish on
the sector as a Republican-led Congress and administration could enact reforms to free cash held overseas for tax reason by large
US pharmaceutical companies, which could pave the way for increased acquisitions in the sector. These stocks research reports can
be downloaded now by simply registering for free at:
http://stock-callers.com/registration
Anthera Pharma
Hayward, California headquartered Anthera Pharmaceuticals Inc.'s shares rose 0.58%, finishing
last Friday's session at $0.69, with a total trading volume of 884,859 shares. Over the last month
and since the start of this year, the stock has advanced 34.89% and 6.96%, respectively. The Company's shares are trading below
their 50-day moving average by 23.90%. Additionally, shares of Anthera Pharma, which focuses on the development and
commercialization of medicines for patients with unmet medical needs, have a Relative Strength Index (RSI) of 39.20.
As per a SEC filing dated February 16 th, 2017, Anthera Pharma received a letter from
the Listing Qualifications Staff of The NASDAQ Stock Market on February 10 th, 2017,
informing the Company that for the last 30 consecutive business days, the bid price of Anthera's common stock has closed below
the minimum $1.00 per share requirement for continued inclusion under Nasdaq Listing Rule
5450(a)(1). The letter stated that NASDAQ will provide Anthera Pharma a grace period of 180 calendar days, or until August 09 th, 2017, to regain compliance. Your complete research report on ANTH can be retrieved for
free at:
http://stock-callers.com/registration/?symbol=ANTH
Arrowhead Pharma
On Friday, shares in Pasadena, California headquartered Arrowhead Pharmaceuticals Inc. ended
the session 1.42% higher at $2.15. The stock recorded a trading volume of 423,754 shares. The
Company's shares have gained 17.49% in the last month and 38.71% on an YTD basis. The stock is trading above its 50-day moving
average by 20.91%. Moreover, shares of Arrowhead Pharma, which develops novel drugs to treat intractable diseases in the US, have
an RSI of 61.63.
On February 06 th, 2017, Arrowhead reported revenue of $43.65
million for Q1 FY17, compared to revenue of $43.75 thousand for Q1 FY16. The Company posted
net loss of $120.86 million, or $0.17 per share, for Q1 FY17 compared
to net loss of $192.64 million, or $0.32 per share, for Q1 FY16. A
free report on ARWR is just a click away at:
http://stock-callers.com/registration/?symbol=ARWR
Pacific Biosciences of California
Menlo Park, California headquartered Pacific Biosciences of California Inc.'s stock climbed
0.79%, to close the day at $5.12, with a total trading volume of 822,250 shares. The Company's
shares have advanced 3.85% in the last one month and 34.74% on an YTD basis. The stock is trading 7.15% above its 50-day moving
average. Additionally, shares of Pacific Biosciences of California, which designs, develops, and
manufactures sequencing systems to resolve genetically complex problems, have an RSI of 57.24.
On February 02 nd, 2017, Pacific Biosciences announced that revenue for Q4 2016
totaled $25.7 million, compared to $36.3 million for Q4 2015. The
Company's Product and service revenue for Q4 2016 increased 92.2% to $24.4 million, compared to
$12.7 million for Q4 2015. Pacific Biosciences' gross profit for Q4 2016 was $11.4 million, resulting in a gross margin of 44.2%, compared to gross profit of $26.5
million and a gross margin of 72.9%, respectively, for Q4 2015. The Company's net loss for Q4 2016 was $19.0 million, compared to a net loss of $1.4 million for Q4 2015. Sign up for
your complimentary research report on PACB at:
http://stock-callers.com/registration/?symbol=PACB
Conatus Pharma
Shares in San Diego, California headquartered Conatus Pharmaceuticals Inc. recorded a trading
volume of 130,754 shares. The stock ended at $4.95, rising 2.70% from the last trading session. The
Company's shares have gained 11.49% in the past month and 164.71% over the previous three months. The stock is trading above its
50-day and 200-day moving averages by 9.90% and 87.66%, respectively. Furthermore, shares of Conatus Pharma, which focuses on the
development and commercialization of novel medicines to treat liver diseases in the US, have an RSI of 53.52.
On February 07 th, 2017, Conatus Pharma announced the appointment of William R. LaRue as an additional independent member to Conatus Pharma's Board of Directors. Mr. LaRue also
will serve as Chair of the Audit Committee. Mr. LaRue currently serves as a member of Tracon Pharmaceuticals, Inc.'s Board of
Directors and Chair of the Audit Committee, and as a member of Applied Proteomics' Board of Directors and Chair of Audit
Committee. Register for free on Stock-Callers.com and download the latest research report on CNAT at:
http://stock-callers.com/registration/?symbol=CNAT
--
Stock Callers:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment
newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments.
One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports
covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered
analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and
micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES :
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a
third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on
analyst credentials, please email info@stock-callers.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document
templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is
believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed
any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently
reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or
interfere in the application of such procedures by the third-party research service company to the articles, documents or
reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or
the Reviewer in any way.
NO WARRANTY
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this
document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss
arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or
liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document.
Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing
of the information, or (2) warrant any results from use of the information. The included information is subject to change without
notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities
mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers
in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with
any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
http://stock-callers.com/legal-disclaimer/
CONTACT
For any questions, inquiries, or comments reach out to us directly. If you ' re
a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between
09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: info@stock-callers.com
Phone number: +44-330-808-3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA